Most medicinal cannabis products are unapproved therapeutic goods, which means they have not been assessed by the TGA for safety, quality or effectiveness. However, where clinically appropriate, there are pathways for doctors to access medicinal cannabis products for their patients.
Therapeutic Goods Administration (TGA)
Australian Government Department of Health
Main menu
- Home
- Safety information
- Report a problem or side effect
- Alerts
- Recalls
- Prescription opioids
- Medicine shortages
- Early warning system
- Black Triangle Scheme
- Safety information & education
- COVID-19
- COVID-19 vaccines
- COVID-19 vaccine approval process
- COVID-19 vaccines undergoing evaluation
- Provisional registrations
- COVID-19 vaccine safety monitoring and reporting
- News and updates
- COVID-19 vaccine advertising and import compliance
- Information for consumers and health professionals
- Information for sponsors (industry)
- International collaboration
- International COVID-19 vaccines recognised by Australia
- COVID-19 treatments
- COVID-19 treatment: Celltrion Healthcare Australia Pty Ltd, regdanvimab (REGKIRONA)
- COVID-19 treatment: Roche Products Pty Ltd, tocilizumab (ACTEMRA)
- COVID-19 treatments: Provisional determinations
- COVID-19 treatments: Provisional registrations
- COVID-19 treatments: Treatments undergoing evaluation
- COVID-19 treatments: Advertising compliance
- COVID-19 treatments: Information for consumers and health professionals
- COVID-19 treatments: Information for sponsors (industry)
- COVID-19 tests
- How testing works for COVID-19
- COVID-19 point-of-care tests
- COVID-19 rapid antigen self-tests
- COVID-19 rapid antigen tests - information for manufacturers and sponsors
- COVID-19 testing in Australia - information for health professionals
- Advertising COVID-19 rapid antigen point-of-care tests and self-tests (home use tests)
- Post market review of COVID-19 point-of-care tests
- Consumers
- Health professionals
- Report a problem or side effect
- Accessing unapproved products
- Advertising
- Medicines
- Medical devices
- Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL)
- Breast implant hub
- Changes to labelling and regulation of hard surface disinfectants (commencing 1 April 2019)
- Information for medical practitioners on pending up-classification of surgical mesh devices
- Patient information material for implantable medical devices
- Importing & supplying medical devices
- Advice about medical devices for health professionals
- Biologicals
- Safety information
- Other resources
- Health professional information & education
- Industry
- SME Assist
- Regulation basics
- How therapeutic goods are regulated in Australia
- Australian Register of Therapeutic Goods
- Industry educational materials
- Legislation & legislative instruments
- Advertising hub
- Labelling & packaging
- Ingredients in therapeutic goods
- Exporting therapeutic goods
- Importing therapeutic goods
- Clinical trials
- Cosmetics
- International scientific guidelines
- Safety information for industry
- Medicine shortages
- Review of real world evidence and patient reported outcomes
- Advertising therapeutic goods
- Prescription medicines
- Over-the-counter medicines
- Complementary medicines
- Sunscreens
- Medical devices & IVDs
- Australian conformity assessment bodies
- Conformity assessment certificates, changes to requirements for certain medical devices
- Consent for Non-compliant Medical Device(s) - Frequently Asked Questions
- Determinations for Australian conformity assessment bodies
- Face masks and COVID-19
- Medical devices regulation basics
- Overview of medical devices and IVD regulation
- Unique Device Identification system
- IVD medical devices regulation basics
- Standards, guidelines and publications
- Forms for medical device & IVD sponsors
- Medical devices reforms
- Regulatory decisions and notices
- Biologicals
- Blood and blood components
- Other therapeutic goods
- Manufacturing therapeutic goods
- Manufacturing basics
- Manufacturing medicines
- Manufacturing medical devices & IVDs
- Manufacturing biologicals
- Manufacturing blood and blood components
- Manufacturing inspections
- Forms for manufacturers
- Notices for manufacturers
- Notices about GMP clearance
- Guidance on the management of GMP compliance signals
- Scheduling of medicines & poisons
- About the TGA
- News room